Demonstrates how some of the most accomplished and elite scientific gatekeepers may have lied, cheated, squandered trust and endangered lives. --The Wall Street Journal

For readers of Empire of Pain and Dopesick, an arresting deep dive into how Alzheimer's disease treatment has been set back by corrupt researchers, negligent regulators, and the profit motives of Big Pharma.

Nearly seven million Americans live with Alzheimer's disease, a tragedy that is already projected to grow into a $1 trillion crisis by 2050. While families suffer and promises of pharmaceutical breakthroughs keep coming up short, investigative journalist Charles Piller's Doctored shows that we've quite likely been walking the wrong path to finding a cure all along--led astray by a cabal of self-interested researchers, government accomplices, and corporate greed.

Piller begins with a whistleblower--Vanderbilt professor Matthew Schrag--whose work exposed a massive scandal. Schrag found that a University of Minnesota lab led by a precocious young scientist and a Nobel Prize-rumored director delivered apparently falsified data at the heart of the leading hypothesis about the disease. Piller's revelations of Schrag's findings stunned the field and the public.

From there, based on years of investigative reporting, this seminal account of deceit that will long be remembered (Katherine Eban, author of Bottle of Lies and Vanity Fair special correspondent) exposes a vast network of deceit and its players, all the way up to the FDA. Piller uncovers evidence that hundreds of important Alzheimer's research papers are based on false data. In the process, he reveals how even against a flood of money and influence, a determined cadre of scientific renegades have fought back to challenge the field's institutional powers in service to science and the tens of thousands of patients who have been drawn into trials to test dubious drugs. It is a shocking tale with huge ramifications not only for Alzheimer's disease, but for scientific research, funding, and oversight at large.

NEW YORK TIMES BESTSELLER - A NEW YORK TIMES NOTABLE BOOK OF THE YEAR - A grand, devastating portrait of three generations of the Sackler family, famed for their philanthropy, whose fortune was built by Valium and whose reputation was destroyed by OxyContin. From the prize-winning and bestselling author of Say Nothing.

A real-life version of the HBO series Succession with a lethal sting in its tail...a masterful work of narrative reportage. - Laura Miller, Slate

The history of the Sackler dynasty is rife with drama--baroque personal lives; bitter disputes over estates; fistfights in boardrooms; glittering art collections; Machiavellian courtroom maneuvers; and the calculated use of money to burnish reputations and crush the less powerful. The Sackler name has adorned the walls of many storied institutions--Harvard, the Metropolitan Museum of Art, Oxford, the Louvre. They are one of the richest families in the world, but the source of the family fortune was vague--until it emerged that the Sacklers were responsible for making and marketing a blockbuster painkiller that was the catalyst for the opioid crisis.

Empire of Pain is the saga of three generations of a single family and the mark they would leave on the world, a tale that moves from the bustling streets of early twentieth-century Brooklyn to the seaside palaces of Greenwich, Connecticut, and Cap d'Antibes to the corridors of power in Washington, D.C. It follows the family's early success with Valium to the much more potent OxyContin, marketed with a ruthless technique of co-opting doctors, influencing the FDA, downplaying the drug's addictiveness. Empire of Pain chronicles the multiple investigations of the Sacklers and their company, and the scorched-earth legal tactics that the family has used to evade accountability.

A masterpiece of narrative reporting, Empire of Pain is a ferociously compelling portrait of America's second Gilded Age, a study of impunity among the super-elite and a relentless investigation of the naked greed that built one of the world's great fortunes.

NEW YORK TIMES BESTSELLER - A NEW YORK TIMES NOTABLE BOOK OF THE YEAR - A grand, devastating portrait of three generations of the Sackler family, famed for their philanthropy, whose fortune was built by Valium and whose reputation was destroyed by OxyContin. From the prize-winning and bestselling author of Say Nothing.

A real-life version of the HBO series Succession with a lethal sting in its tail...a masterful work of narrative reportage. - Laura Miller, Slate

The history of the Sackler dynasty is rife with drama--baroque personal lives; bitter disputes over estates; fistfights in boardrooms; glittering art collections; Machiavellian courtroom maneuvers; and the calculated use of money to burnish reputations and crush the less powerful. The Sackler name has adorned the walls of many storied institutions--Harvard, the Metropolitan Museum of Art, Oxford, the Louvre. They are one of the richest families in the world, but the source of the family fortune was vague--until it emerged that the Sacklers were responsible for making and marketing a blockbuster painkiller that was the catalyst for the opioid crisis.

Empire of Pain is the saga of three generations of a single family and the mark they would leave on the world, a tale that moves from the bustling streets of early twentieth-century Brooklyn to the seaside palaces of Greenwich, Connecticut, and Cap d'Antibes to the corridors of power in Washington, D.C. It follows the family's early success with Valium to the much more potent OxyContin, marketed with a ruthless technique of co-opting doctors, influencing the FDA, downplaying the drug's addictiveness. Empire of Pain chronicles the multiple investigations of the Sacklers and their company, and the scorched-earth legal tactics that the family has used to evade accountability.

A masterpiece of narrative reporting, Empire of Pain is a ferociously compelling portrait of America's second Gilded Age, a study of impunity among the super-elite and a relentless investigation of the naked greed that built one of the world's great fortunes.

For Blood and Money tells the little-known story of how an upstart biotechnology company created a one-in-a-million cancer drug, and how the core team--denied their share of the profits--went and did it again. In this epic saga of money and science, veteran financial journalist Nathan Vardi explains how the invention of two of the biggest cancer drugs in history became (for their backers) two of the greatest Wall Street bets of all time.

In the multibillion-dollar business of biotech, where pharmaceutical companies, the government, hedge funds, and venture capitalists have spent billions on funding, experimentation, and treatments, a single molecule can stop cancer in its tracks--and make the people who find that rare molecule astonishingly rich. For Blood and Money follows a small team at a biotech start-up in California, who have found one of these rare molecules. Their compound, known as a BTK inhibitor, seems to work on a vicious type of leukemia. When patients start rising from their hospice beds, the team knows they're onto something big.

What follows is a story of genius, pathos, and drama, in which vivid characters navigate a world of corporate intrigue and ambiguous morality. Vardi's narrative immerses readers in the recent explosion of biotech start-ups. He describes the scientists, doctors, and investors who are risking everything to develop new, life-saving treatments, and introduces suffering patients for whom the stakes are life-or-death. A gripping nonfiction read, For Blood and Money illustrates why it's so hard to bring new drugs to market, explains why they are so expensive, and examines how profit-driven venture capitalists are shaping the future of medicine.

In this timely and much praised book, Barry Werth draws upon inside reporting that spans more than two decades. He provides a groundbreaking close-up of the upstart pharmaceutical company Vertex and the ferocious but indispensable world of Big Pharma that it inhabits.

In 1989, the charismatic Joshua Boger left Merck, then America's most admired business, to found a drug company that would challenge industry giants and transform health care. Werth described the company's tumultuous early days during the AIDS crisis in The Billion-Dollar Molecule, a celebrated classic of science and business journalism. Now he returns to tell a riveting story of Vertex's bold endurance and eventual success.

The $325 billion-a-year pharmaceutical business is America's toughest and one of its most profitable. It's riskier and more rigorous at just about every stage than any other business, from the towering biological uncertainties inherent in its mission to treat disease; to the 30-to-1 failure rate in bringing out a successful medicine even after a molecule clears all the hurdles to get to human testing; to the multibillion-dollar cost of ramping up a successful product; to operating in the world's most regulated industry, matched only by nuclear power.

Werth captures the full scope of Vertex's twenty-five-year drive to deliver breakthrough medicines. At a time when America struggles to maintain its innovative edge, The Antidote is a powerful inside look at one of the most intriguing and important business stories of recent decades.

Developing life-changing drugs is risky and expensive--but that's not what makes them unaffordable.

Drug pricing is a staple of every news cycle and political debate. And while we've struggled for decades to agree on solutions that serve all patients without jeopardizing the invention of new medicines, many Americans suffer because they can't afford the drugs they need.

Do we really have to choose between affordability and innovation?

In The Great American Drug Deal, scientist and industry expert Peter Kolchinsky answers this question with a decisive No. The pharmaceutical industry's commitment to creating new lifesaving drugs destined to become inexpensive generics can be balanced by the healthcare system's commitment to making those drugs affordable for all patients--a Biotech Social Contract. Through deep research and compelling stories of breakthroughs and breakdowns, Kolchinsky presents solutions for striking a balance that are bold yet realistic and tackle today's most pressing questions, including:

• Why doesn't insurance make drugs affordable?
• How can we prevent price-jacking of older drugs?
• Why are drugs more expensive in America than elsewhere?
• How can we guarantee that all medicines eventually go generic so they are only temporarily expensive?
• What systemic failures led to the opioid crisis, and how can we prevent the next one?

The Great American Drug Deal offers clear-eyed scrutiny of all players in the industry and examines vital ideas for closing loopholes, encouraging investment, dealing with bad actors, and educating consumers. It's time we resolve to support patients and fuel discoveries that ease suffering now and for generations to come.

A haunting (Anne Helen Petersen, author of Can't Even) and deeply personal investigation of an underground for-profit medical industry and the American underclass it drains for blood and profit.

Journalist Kathleen McLaughlin knew she'd found a treatment that worked on her rare autoimmune disorder. She had no idea it had been drawn from the veins of America's most vulnerable.

So begins McLaughlin's ten-year investigation researching and reporting on the $20-billion-a year business she found at the other end of her medication, revealing a vampiric real-life story of modern-day greed (Leah Sottile, host of Bundyville). Assigned to work in China, where the plasma supply had been rocked by numerous scandals, McLaughlin hid American plasma in her luggage during trips between the two countries. And when she was warned by a Chinese researcher of troubling echoes between America's domestic plasma supply chain and the one she'd seen spin out into chaos in China, she knew she had to dig deeper.

Blood Money shares McLaughlin's decade-long mission to learn the full story of where her medicine comes from. She travels the United States in search of the truth about human blood plasma and learns that twenty million Americans each year sell their plasma for profit--a human-derived commodity extracted inside our borders to be processed and packaged for retail across the globe. She investigates the thin evidence pharmaceutical companies have used to push plasma as a wonder drug for everything from COVID-19 to wrinkled skin. And she unearths an American economic crisis hidden in plain sight: single mothers, college students, laid-off Rust Belt auto workers, and a booming blood market at America's southern border, where collection agencies target Mexican citizens willing to cross over and sell their plasma for substandard pay.

This captivating and anguished exposé (Publishers Weekly) weaves together McLaughlin's personal battle to overcome illness while also facing her own complicity in this wheel of exploitation with an electrifying portrait of big business run amok.

For Blood and Money tells the little-known story of how an upstart biotechnology company created a one-in-a-million cancer drug, and how members of the core team--denied their share of the profits--went and did it again. In this epic saga of money and science, veteran financial journalist Nathan Vardi explains how the invention of two of the biggest cancer drugs in history became (for their backers) two of the greatest Wall Street bets of all time.

In the multibillion-dollar business of biotech, where pharmaceutical companies, the government, hedge funds, and venture capitalists have spent billions on funding, experimentation, and treatments, a single molecule can stop cancer in its tracks--and make the people who find that rare molecule astonishingly rich. For Blood and Money follows a small team at a biotech start-up in California, who have found one of these rare molecules. Their compound, known as a BTK inhibitor, seems to work on a vicious type of leukemia. When patients start rising from their hospice beds, the team knows they're onto something big.

What follows is a story of genius, pathos, and drama, in which vivid characters navigate a world of corporate intrigue and ambiguous morality. Vardi's narrative immerses readers in the recent explosion of biotech start-ups. He describes the scientists, doctors, and investors who are risking everything to develop new, life-saving treatments, and introduces suffering patients for whom the stakes are life-or-death. A gripping nonfiction read, For Blood and Money illustrates why it's so hard to bring new drugs to market, explains why they are so expensive, and examines how profit-driven venture capitalists are shaping the future of medicine.

Building Biotechnology helps readers start and manage biotechnology companies and understand the business of biotechnology. This acclaimed book describes the convergence of scientific, policy, regulatory, and commercial factors that drive the biotechnology industry and define its scope. In addition to its popularity among business professionals and scientists seeking to apply their skills to biotechnology, Building Biotechnology has also been adopted as a course text in dozens of advanced biotechnology programs. This fourth edition significantly expands upon the foundation laid by the first three, updating case law and business models in this dynamic industry and adding significantly more case studies, informative figures and tables. Most importantly, Building Biotechnology enables seasoned business professionals and entrepreneurial scientists alike to understand the drivers of biotechnology businesses and apply their established skills for commercial success.

The inside story of an unprecedented feat of science and business.

At the start of 2020, Moderna was a biotech unicorn with dim prospects. Yes, there was the promise of its disruptive innovation that could transform medicine by using something called messenger RNA, one of the body's building blocks of life, to combat disease. But its stock was under water. There were reports of a toxic work culture. And despite ten years of work, the company was still years away from delivering its first product. Investors were getting antsy, or worse, skeptical.

Then the pandemic hit, and Moderna, at first reluctantly, became a central player in a global drama--a David to Big Pharma's Goliaths--turning its technology toward breaking the global grip of the terrible disease. By year's end, with the virus raging, Moderna delivered one of the world's first Covid-19 vaccines, with a stunningly high rate of protection. The achievement gave the world a way out of a crippling pandemic while validating Moderna's technology, transforming the company into a global industry power. Biotech, and the venture capital community that fuels it, will never be the same.

Wall Street Journal reporter Peter Loftus, veteran reporter covering the pharmaceutical and biotech industries and part of a Pulitzer Prize-finalist team, brings the inside story of Moderna, from its humble start at a casual lunch through its heady startup days, into the heart of the pandemic and beyond. With deep access to all of the major players, Loftus weaves a tale of science and business that brings to life Moderna's monumental feat of creating a vaccine that beat back a deadly virus and changed the business of medicine forever.

The Messenger spans a decade and is full of heroic efforts by ordinary people, lucky breaks, and life-and-death decisions. It's the story of a revolutionary idea, the evolution of a cutting-edge American industry, and one of the great achievements of this century.

Consumers and Patients are exposed to risks when taking substandard or counterfeit drugs. Every day, an army of dedicated individuals works tirelessly to protect patients. For every measure implemented to protect patients, another army is working just as hard trying to nullify these efforts so they can sell substandard and counterfeit drugs to unsuspecting consumers and patients. This book is designed to provide consumer awareness of the threats and a roadmap for young professionals to develop into influential quality professionals.

The book is divided into eight chapters that covers key aspects of pharmaceutical market access in emerging markets. From understanding the healthcare environment, to the personal and organizational mindset, to pricing, market access solutions and negotiations. The book is based on practical experience that gives the reader knowledge and know-how to apply practical market access solutions to improve access to innovative medicine in emerging markets.

If you work in or around biotech, you're supposed to understand clinical trial results. But what if you're not an expert in study design or biostatistics? You may feel out of your comfort zone when faced with a journal article, press release, or investor presentation.

The Pharmagellan Guide to Analyzing Biotech Clinical Trials is a comprehensive primer to help non-experts evaluate clinical studies of new therapies.

• Structured roadmap for assessing the main components of a planned or completed biotech trial.
• Clear explanations of the most common concepts and terms in biotech clinical studies, illustrated with over 100 real-world examples.
• Deep dives on essential topics like p values, sample size calculations, and Kaplan-Meier curves, written in plain English for non-statisticians.
• Pointers for interpreting positive and negative study results, understanding common figures and tables, and identifying red flags in press releases.

If you're a biotech executive, investor, advisor, or entrepreneur - or aspire to be one - this handbook will give you the foundation you need to analyze planned and completed clinical trials with more confidence.

From the nation's leading experts in healthcare safety--the first comprehensive guide to delivering care that ensures the safety of patients and staff alike. One of the primary tenets among healthcare professionals is, First, do no harm. Achieving this goal means ensuring the safety of both patient and caregiver. Every year in the United States alone, an estimated 4.8 million hospital patients suffer serious harm that is preventable. To address this industry-wide problem--and provide evidence-based solutions--a team of award-winning safety specialists from Press Ganey/Healthcare Performance Improvement have applied their decades of experience and research to the subject of patient and workforce safety. Their mission is to achieve zero harm in the healthcare industry, a lofty goal that some hospitals have already accomplished--which you can, too.
Combining the latest advances in safety science, data technology, and high reliability solutions, this step-by-step guide shows you how to implement 6 simple principles in your workplace.
1. Commit to the goal of zero harm.2. Become more patient-centric.3. Recognize the interdependency of safety, quality, and patient-centricity.4. Adopt good data and analytics.5. Transform culture and leadership.6. Focus on accountability and execution. In Zero Harm, the world's leading safety experts share practical, day-to-day solutions that combine the latest tools and technologies in healthcare today with the best safety practices from high-risk, yet high-reliability industries, such as aviation, nuclear power, and the United States military. Using these field-tested methods, you can develop new leadership initiatives, educate workers on the universal skills that can save lives, organize and train safety action teams, implement reliability management systems, and create long-term, transformational change. You'll read case studies and success stories from your industry colleagues--and discover the most effective ways to utilize patient data, information sharing, and other up-to-the-minute technologies. It's a complete workplace-ready program that's proven to reduce preventable errors and produce measurable results--by putting the patient, and safety, first.

For readers of Bad Blood and Empire of Pain, an authoritative look at monopoly medicine from the dawn of patents through the race for COVID-19 vaccines and how the privatization of public science has prioritized profits over people

Owning the Sun tells the story of one of the most contentious fights in human history: the legal right to produce lifesaving medicines. Medical science began as a discipline geared toward the betterment of all human life, but the merging of research with intellectual property and the rise of the pharmaceutical industry warped and eventually undermined its ethical foundations. Since World War II, federally funded research has facilitated most major medical breakthroughs, yet these drugs are often wholly controlled by price-gouging corporations with growing international ambitions. Why does the U.S. government fund the development of medical science in the name of the public only to relinquish exclusive rights to drug companies, and how does such a system impoverish us, weaken our responses to crises, and, as in the cases of AIDS and COVID-19, put the world at risk?

Outlining how generations of public health and science advocates have attempted to hold the line against Big Pharma and their allies in government, Alexander Zaitchik's first-of-its-kind history documents the rise of privatized medicine in the United States and its subsequent globalization. From the controversial arrival of patent-wielding German drug firms in the late nineteenth century to present-day coordination between industry and philanthropic organizations--including the influential Bill & Melinda Gates Foundation--that stymie international efforts to vaccinate the world against COVID-19, Owning the Sun tells one of the most important and least understood histories of our time.

Wall Street Journal Bestseller

2022 Genesis Prize Laureate

Axiom Award Bronze Medalist for Business Intelligence / Innovation

The exclusive, first-hand, behind-the-scenes story of how Pfizer raced to create the first Covid-19 vaccine, told by Pfizer's Chairman and CEO Dr. Albert Bourla.

A riveting, fast-paced, inside look at one of the most incredible private sector achievements in history, Moonshot recounts the intensive nine months in 2020 when the scientists at Pfizer, under the visionary leadership of Dr. Albert Bourla, made the impossible possible--creating, testing, and manufacturing a safe and effective Covid-19 vaccine that previously would have taken years to develop.

Dr. Bourla chronicles how the brilliant, dedicated minds at Pfizer, under the enormous strains of the global pandemic, overcame a series of crises that were compounded by social and political unrest, and reveals the doubts, decisions, obstacles, and failures they encountered. As Dr. Bourla makes clear, Pfizer's success wasn't due to luck; it was because of preparation driven by four simple values--Courage, Excellence, Equity, and Joy.

Moonshot is a story of leadership under the most unprecedented circumstances--how Dr. Bourla, a Greek immigrant, a child of Holocaust survivors, and a veterinarian, became the head of one of the world's largest corporations and initiated a dramatic transformation of the organization just before a global health crisis would serve to test the organization, its scientists, and its leader, like never before. Moonshot describes best practices that can be used to address the multiple, unprecedented challenges our world faces, reveals Pfizer's implementation of scientific breakthroughs at a record-breaking pace, and offers leadership lessons that can help anyone successfully manage their own seemingly unsolvable problems. As Dr. Bourla explains, I am sharing the story of our moonshot--the challenges we faced, the lessons we learned, and the core values that allowed us to make it happen--in hopes that it might inspire and inform your own moonshot, whatever that may be.

During her two decades at The New England Journal of Medicine, Dr. Marcia Angell had a front-row seat on the appalling spectacle of the pharmaceutical industry. She watched drug companies stray from their original mission of discovering and manufacturing useful drugs and instead become vast marketing machines with unprecedented control over their own fortunes. She saw them gain nearly limitless influence over medical research, education, and how doctors do their jobs. She sympathized as the American public, particularly the elderly, struggled and increasingly failed to meet spiraling prescription drug prices. Now, in this bold, hard-hitting new book, Dr. Angell exposes the shocking truth of what the pharmaceutical industry has become-and argues for essential, long-overdue change.

Currently Americans spend a staggering $200 billion each year on prescription drugs. As Dr. Angell powerfully demonstrates, claims that high drug prices are necessary to fund research and development are unfounded: The truth is that drug companies funnel the bulk of their resources into the marketing of products of dubious benefit. Meanwhile, as profits soar, the companies brazenly use their wealth and power to push their agenda through Congress, the FDA, and academic medical centers.

Zeroing in on hugely successful drugs like AZT (the first drug to treat HIV/AIDS), Taxol (the best-selling cancer drug in history), and the blockbuster allergy drug Claritin, Dr. Angell demonstrates exactly how new products are brought to market. Drug companies, she shows, routinely rely on publicly funded institutions for their basic research; they rig clinical trials to make their products look better than they are; and they use their legions of lawyers to stretch out government-granted exclusive marketing rights for years. They also flood the market with copycat drugs that cost a lot more than the drugs they mimic but are no more effective.

The American pharmaceutical industry needs to be saved, mainly from itself, and Dr. Angell proposes a program of vital reforms, which includes restoring impartiality to clinical research and severing the ties between drug companies and medical education. Written with fierce passion and substantiated with in-depth research, The Truth About the Drug Companies is a searing indictment of an industry that has spun out of control.

Bullseyes and Blunders: Lessons from 100 Cases in Pharmaceutical Marketing is a first-of-its-kind of a book. The book is an invaluable resource for the practitioners as well as the students of pharmaceutical marketing. The case studies presented in the book offer many experiential insights into how some of the world's renowned pharmaceutical marketers built, launched, defended and managed their brands and steered them clear of competition. The Bullseyes in the book present a snapshot of these winning brands.

Studying the Blunders or failures or flops too is significant for the practitioners and students of marketing alike. Because these provide the much-needed insights into the essential, Don'ts while building and managing their brands.

Bullseyes and Blunders provides a more practical understanding of various topics that are highly relevant for the Pharma brand managers and marketing managers. These are market opportunity analysis, product positioning, product launches, life cycle management, building and defending a disease-franchise among others.

Contents:

1. The Pharmaceutical Market

2. The Pharmaceutical Product

3. Therapeutic Leadership

4. Product Launch Strategy

5. Life Cycle Management

6. Pharmaceutical Marketing Practices: Good and Bad

7. Disease Branding

8. Blue Ocean Strategy

9. The Pricing Strategies

10. Pharma and Social Media

Building Biotechnology helps readers start and manage biotechnology companies and understand the business of biotechnology. This acclaimed book describes the convergence of scientific, policy, regulatory, and commercial factors that drive the biotechnology industry and define its scope. In addition to its popularity among business professionals and scientists seeking to apply their skills to biotechnology, Building Biotechnology has also been adopted as a course text in dozens of advanced biotechnology programs. This fourth edition significantly expands upon the foundation laid by the first three, updating case law and business models in this dynamic industry and adding significantly more case studies, informative figures and tables. Most importantly, Building Biotechnology enables seasoned business professionals and entrepreneurial scientists alike to understand the drivers of biotechnology businesses and apply their established skills for commercial success.